Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery

Knowledge and investigation of therapeutic targets (responsible for drug efficacy) and the targeted drugs facilitate target and drug discovery and validation. Therapeutic Target Database (TTD, http://bidd.nus.edu.sg/group/ttd/ttd.asp) has been developed to provide comprehensive information about efficacy targets and the corresponding approved, clinical trial and investigative drugs. Since its last update, major improvements and updates have been made to TTD. In addition to the significant increase of data content (from 1894 targets and 5028 drugs to 2025 targets and 17 816 drugs), we added target validation information (drug potency against target, effect against disease models and effect of target knockout, knockdown or genetic variations) for 932 targets, and 841 quantitative structure activity relationship models for active compounds of 228 chemical types against 121 targets. Moreover, we added the data from our previous drug studies including 3681 multi-target agents against 108 target pairs, 116 drug combinations with their synergistic, additive, antagonistic, potentiative or reductive mechanisms, 1427 natural product-derived approved, clinical trial and pre-clinical drugs and cross-links to the clinical trial information page in the ClinicalTrials.gov database for 770 clinical trial drugs. These updates are useful for facilitating target discovery and validation, drug lead discovery and optimization, and the development of multi-target drugs and drug combinations.

[1]  Michael J. Sorich,et al.  Comparison Data Sets for Benchmarking QSAR Methodologies in Lead Optimization , 2009, J. Chem. Inf. Model..

[2]  Gerhard Klebe,et al.  Comparison of Automatic Three-Dimensional Model Builders Using 639 X-ray Structures , 1994, J. Chem. Inf. Comput. Sci..

[3]  Martti T Tammi,et al.  What Are Next Generation Innovative Therapeutic Targets? Clues from Genetic, Structural, Physicochemical, and Systems Profiles of Successful Targets , 2009, Journal of Pharmacology and Experimental Therapeutics.

[4]  Janice M Reichert,et al.  Current trends in the clinical development of peptide therapeutics. , 2009, IDrugs : the investigational drugs journal.

[5]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[6]  D. Hewitt,et al.  Challenges in Analgesic Drug Development , 2009, Clinical pharmacology and therapeutics.

[7]  D. Newman,et al.  Natural products as sources of new drugs over the last 25 years. , 2007, Journal of natural products.

[8]  Wendy A. Warr,et al.  ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI) , 2009, J. Comput. Aided Mol. Des..

[9]  S D Kemp,et al.  Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. , 1995, Science.

[10]  Jonathan Knowles,et al.  A guide to drug discovery: Target selection in drug discovery , 2003, Nature Reviews Drug Discovery.

[11]  Arvind Saklani,et al.  Plant-derived compounds in clinical trials. , 2008, Drug discovery today.

[12]  Christopher M Overall,et al.  Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. , 2006, Nature reviews. Cancer.

[13]  Hongyu Zhao,et al.  Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. , 2007, Drug discovery today.

[14]  Y. Z. Chen,et al.  Therapeutic Targets: Progress of Their Exploration and Investigation of Their Characteristics , 2006, Pharmacological Reviews.

[15]  Boon Chuan Low,et al.  In-Silico Approaches to Multi-target Drug Discovery , 2010, Pharmaceutical Research.

[16]  Igor V. Tetko,et al.  Virtual Computational Chemistry Laboratory – Design and Description , 2005, J. Comput. Aided Mol. Des..

[17]  J. Reichert,et al.  Development trends for human monoclonal antibody therapeutics , 2010, Nature Reviews Drug Discovery.

[18]  Lu Huang,et al.  Update of TTD: Therapeutic Target Database , 2009, Nucleic Acids Res..

[19]  B. Vanhaesebroeck,et al.  Killing two kinase families with one stone. , 2008, Nature chemical biology.

[20]  C W Yap,et al.  Regression methods for developing QSAR and QSPR models to predict compounds of specific pharmacodynamic, pharmacokinetic and toxicological properties. , 2007, Mini reviews in medicinal chemistry.

[21]  D. Sprous,et al.  QSAR in the pharmaceutical research setting: QSAR models for broad, large problems. , 2010, Current topics in medicinal chemistry.

[22]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[23]  John P. Overington.  ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI). Interview by Wendy A. Warr. , 2009, Journal of computer-aided molecular design.

[24]  M. Lindsay.  Target discovery , 2003, Nature Reviews Drug Discovery.

[25]  W. Stumpf,et al.  Memo to the FDA and ICH: appeal for in vivo drug target identification and target pharmacokinetics Recommendations for improved procedures and requirements. , 2007, Drug discovery today.

[26]  Eliezer J Barreiro,et al.  Privileged structures: a useful concept for the rational design of new lead drug candidates. , 2007, Mini reviews in medicinal chemistry.

[27]  Gregory D. Schuler,et al.  Database resources of the National Center for Biotechnology Information: update , 2004, Nucleic acids research.

[28]  H. Echchakir,et al.  In vivo target validation using gene invalidation, RNA interference and protein functional knockout models: it is the time to combine. , 2009, Current opinion in pharmacology.

[29]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[30]  C. Yap,et al.  Progress and problems in the exploration of therapeutic targets. , 2006, Drug discovery today.

[31]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[32]  G. Church,et al.  Identifying regulatory networks by combinatorial analysis of promoter elements , 2001, Nature Genetics.

[33]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[34]  Steven Kozlowski,et al.  The FDA's assessment of follow-on protein products: a historical perspective , 2007, Nature Reviews Drug Discovery.

[35]  X. Chen,et al.  TTD: Therapeutic Target Database , 2002, Nucleic Acids Res..

[36]  B. Stockwell,et al.  Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.

[37]  A. Sands,et al.  Knockouts model the 100 best-selling drugs—will they model the next 100? , 2003, Nature Reviews Drug Discovery.

[38]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[39]  J. Vederas,et al.  [Drug discovery and natural products: end of era or an endless frontier?]. , 2011, Biomeditsinskaia khimiia.

[40]  Irena Melnikova,et al.  RNA-based therapies , 2007, Nature Reviews Drug Discovery.

[41]  Jerry J Buccafusco,et al.  Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. , 2005, Trends in pharmacological sciences.

[42]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[43]  Christopher M. Overall,et al.  Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.

[44]  M. Butler.  Natural products to drugs: natural product-derived compounds in clinical trials. , 2005, Natural product reports.

[45]  Tomasz Arodz,et al.  Computational methods in developing quantitative structure-activity relationships (QSAR): a review. , 2006, Combinatorial chemistry & high throughput screening.

[46]  J. D. Elliott,et al.  Drug discovery in the next millennium. , 2000, Annual review of pharmacology and toxicology.

[47]  Y Z Chen,et al.  Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines. , 2010, Molecular pharmaceutics.

[48]  Lin Tao,et al.  Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting , 2011, Proceedings of the National Academy of Sciences.

[49]  Alessandro Pedretti,et al.  Assessing drug-likeness--what are we missing? , 2008, Drug discovery today.

[50]  Zhe Shi,et al.  Computer Aided Multi-target Drug Design, Multi-target Virtual Screening , 2010 .

[51]  Z R Li,et al.  MODEL—molecular descriptor lab: A web‐based server for computing structural and physicochemical features of compounds , 2007, Biotechnology and bioengineering.

[52]  Keith T Flaherty,et al.  Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases , 2006, Molecular Cancer Therapeutics.

[53]  E. Spack,et al.  The basics of preclinical drug development for neurodegenerative disease indications , 2009, BMC neurology.

[54]  M. Rask-Andersen,et al.  Trends in the exploitation of novel drug targets , 2011, Nature Reviews Drug Discovery.

[55]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.